Latent cardiovascular toxicity issues continue to plague late-stage drug discovery efforts, as well as commercially launched pharmaceutical success. Many current in vitro models lack, or incompletely recapitulate, important aspects of human cardiac biology, thus allowing certain toxicities to escape detection until the non-human primate and clinical trial stages of drug development. Induced pluripotent stem cell (iPSC) technology brings relevant human biology to the laboratory and with it, great promise for early predictive detection of cardiotoxicity. This webinar will encompass recent and ongoing work that utilizes human iPSC-cardiomyocytes to detect on- and off-target cardiovascular toxicity. Case studies will be presented that describe specific examples where human cardiomyocytes identified toxicities missed by more traditional assays. Additionally, the scientific panel will provide an overview of how iPS cell-derived cardiomyocytes can be used as front-line predictive screens, as well as a medicinal chemistry tool for designing safer compounds. Together, these presentations will highlight the utility and practical implementation of iPS cell-based technologies for toxicity testing applications and illustrate how iPS cell-derived cardiomyocytes may save resources, increase productivity, and result in safer medicines.
Blake Anson, Ph.D., Product Manager at Cellular Dynamics International, will provide a brief introduction into human iPSC-cardiomyocytes and how they have become a valued part of drug discovery and toxicology research.
Dale Baker, Scientist II Exploratory Toxicology at Celgene, will present the findings from his work using iPSC-cardiomyocytes, hERG cardiac ion channels, and dog telemetry studies as assays used in testing kinase inhibitor toxicity.
Matt Peters, Ph.D., Principal Scientist Discovery Toxicology at AstraZeneca, will describe advances using impedance-based assays with human iPSC-derived cardiomyocytes as front-line screens for detecting functional cardiotoxicity.